PRESS RELEASE: Completes $5.3M Financing Round
Summary
These datasets enable Pharma to accelerate target discovery, identify genetic biomarkers for better clinical trial stratification, and develop CDx for regulatory approval. A comprehensive understanding of Genomics is essential to advancing Precision Medicine, and Genomenon uniquely meets that need in ways that have led to quick adoption in the market. The company’s freemium model makes the Mastermind Genomic Search Engine freely available to a broad range of scientists, academics, and clinicians, and their user base of well over ten thousand extends to more than 118 countries. Skip Simms, Managing Member of Michigan Angel Fund, said of Genomenon “This is a well-run company and world class team of people driving this game-changing technology and service. They build shareholder value every week and we’re delighted to be one of those major shareholders.” Lauren Tyra, Chief Scientific Officer of Green Park & Golf Ventures, said, “We are excited to be supporters of Genomenon’s forward-looking approach to genetic and rare disease diagnosis.
Funding
Classifications
AskAI Classifications
LabelsLinked Companies
